Perioperative dexmedetomidine improves mortality in patients undergoing coronary artery bypass surgery
Fuhai Ji et al

Journal of Cardiothoracic and Vascular Anesthesia
Volume 28, Issue 2 , Pages 267-273, April 2014

Retrospective investigation.
Perioperative dexmedetomidine was used as an intravenous infusion (0.24 to 0.6 µg/kg/hour) initiated after cardiopulmonary bypass and continued for less than 24 hours postoperatively in the intensive care unit.
Dexmedetomidine infusion during CABG surgery was more likely to achieve improved in-hospital, 30-day, and 1-year survival rates, and a significantly lower incidence of delirium.